Related Experiment Video
Updated: Jun 12, 2026
11:53
Laparoscopic Oocyte Retrieval and Cryopreservation during Vaginoplasty for Treatment of Mayer-Rokitansky-Kuster-Hauser Syndrome
Published on: May 10, 2022
Vulvovaginal atrophy: current and future therapies (CME)
1George Washington University Medical Center-Obstetrics and Gynecology, Washington, DC 20036, USA.
The Journal of Sexual Medicine
|May 27, 2010
Summary
Vulvovaginal atrophy treatments, including low-dose local estrogen and intravaginal dehydroepiandrosterone (DHEA), are effective with few side effects. New methods show promise for improved efficacy and safety.
Area of Science:
- Gynecology
- Menopause research
- Pharmacology
Background:
- Vulvovaginal atrophy (VVA) is a common condition in postmenopausal women caused by estrogen deficiency.
- Symptoms of VVA include vaginal dryness, itching, irritation, and painful intercourse (dyspareunia).
Purpose of the Study:
- To review the efficacy, safety, and acceptability of current VVA treatments.
- To highlight emerging therapeutic strategies for VVA.
Main Methods:
- A comprehensive literature review was conducted.
- Studies focused on the treatment of vulvovaginal atrophy were analyzed.
Main Results:
- Low-dose local estrogen formulations are effective and generally safe for managing VVA symptoms.
- Intravaginal dehydroepiandrosterone (DHEA) and selective estrogen receptor modulators (SERMs) demonstrate efficacy without causing endometrial proliferation.
- Concerns from the Women's Health Initiative and FDA recommendations have spurred the development of novel VVA treatments.
Conclusions:
- Current and emerging treatments for VVA offer effective symptom relief with a favorable safety profile.
- Further research is necessary to optimize new treatment formulations for vulvovaginal atrophy.
Related Concept Videos
01:22Mitral Valve Prolapse II: Assessment and Management
IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular tachycardia.
01:19Mitral Valve Prolapse III: Nursing Management
The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
01:24Cystic Fibrosis: Management
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Sinus disease and chronic sinusitis...
01:24Disorders of the Female Reproductive System
The female reproductive system can be affected by several disorders, including Premenstrual Syndrome (PMS), Premenstrual Dysphoric Disorder (PMDD), endometriosis, and various forms of cancer. PMS and PMDD are cyclical conditions that cause physical and emotional distress, with symptoms that include edema, mood swings, and food cravings. PMDD is a more severe form of PMS characterized by increased symptom severity that peaks during the luteal phase and tends to improve or resolve shortly after...
01:20Candidiasis
Candidiasis is a fungal infection caused by opportunistic species of Candida. It can affect various anatomical sites, including the skin, oral cavity, nails, and genitourinary tract. Among its forms, vaginal candidiasis is the most common type of mucosal infection. It typically results from the overgrowth of Candida albicans in the vaginal mucosa. Under normal conditions, C. albicans exists as a commensal organism within the vaginal microbiota, regulated by the dominance of lactobacilli, which...
01:26Peptic Ulcer Disease IV: Management
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...